China Nuokang Bio-Pharmaceutical, a company focused on hematological and cardiovascular drugs, has filed an IPO and will offer 4.5 million American Depositary Shares on the Nasdaq exchange at a price between $10 and $12. In its SEC filing announcing the planned IPO, Nuokang points out that it will likely benefit from the healthcare reform proposal the Chinese government outlined earlier this...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Chinese firm files $69M IPO
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
account